title: ERK-mediated NF-κB activation through ASIC1 in response to acidosis.
abstract: Acidic microenvironment is a common feature of solid tumors. We have previously shown that neuron specific acid-sensing ion channel 1 (ASIC1) is expressed in breast cancer, and it is responsible for acidosis-induced cellular signaling through AKT, leading to nuclear factor-κB (NF-κB) activation, and cell invasion and metastasis. However, AKT is frequently activated in cancer. Thus, a key question is whether ASIC1-mediated cell signaling still takes place in the cancer cells carrying constitutively active AKT. In the present study, we show that among four prostate cancer cell lines tested, 22Rv1 cells express the highest level of phosphorylated AKT that is not impacted by acidosis. However, acidosis can still induce NF-κB activation during which extracellular signal-regulated kinase (ERK) serves as an alternative pathway for ASIC-mediated cell signaling. Inhibition of ERK by chemical inhibitors or small interfering RNAs suppresses the acidosis-induced NF-κB activity through regulation of the inhibitory subunit IκBα phosphorylation. Furthermore, suppression of ASIC1-mediated generation of reactive oxygen species (ROS) by ROS scavengers, such as glutathione or N-acetyl-cysteine causes a decrease in ERK phosphorylation and degradation of IκBα. Finally, ASIC1 is upregulated in a subset of prostate cancer cases and ASIC1 knockout by CRISPR/Cas9 significantly suppresses cell invasion, and castration resistance both in vitro and in vivo. Together, these results support the significance of ASIC1-ROS-ERK-IκBα-NF-κB axis in prostate tumorigenesis, especially in the constitutively active AKT background.
authors.affiliation: Department of Urology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.|Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
authors.forename: B
authors.initials: B
authors.lastname: Chen
authors.affiliation: Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.|Department of Emergency Medicine, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
authors.forename: J
authors.initials: J
authors.lastname: Liu
authors.affiliation: Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.|Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, USA.
authors.forename: T-T
authors.initials: TT
authors.lastname: Ho
authors.affiliation: Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.|College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, China.
authors.forename: X
authors.initials: X
authors.lastname: Ding
authors.affiliation: Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.|Department of Pharmacology/Toxicology, University of Mississippi Medical Center, Jackson, MS, USA.
authors.forename: Y-Y
authors.initials: YY
authors.lastname: Mo